Discussion
We report 1-year outcomes from a single-center experience evaluating the J-Valvefor TA-TAVR in patients with AR. The key findings include 7.4% and 2.2% 1-year mortality and stroke rate, respectively. Echocardiographic measurements confirmed adequate hemodynamic function with a significant improvement in LVEF, a reduction in LVEDD, LVESD, a low rate of residual leakage after TAVR, and excellent aortic valve hemodynamics, with low mean gradients of 8.2±3.2 mmHg maintained to 1-year follow-up.